



The effectiveness of secretomes delivery using microneedling compared to laser-assisted drug delivery for facial skin rejuvenation: a systematic review

A eficácia da administração de secretomas usando microagulhamento ou laser para o rejuvenescimento da pele facial: uma revisão sistemática

DOI: <http://www.dx.doi.org/10.5935/scd1984-8773.2024160274>

ABSTRACT

This study compared the effectiveness of secretome delivery using microneedling versus laser-assisted drug delivery for facial skin rejuvenation. The review included seven studies that demonstrated that both approaches were effective in delivering secretomes. However, microneedling had a higher patient satisfaction rate and fewer reported adverse events. We concluded that micro needling may be a more patient-friendly and safer option for facial rejuvenation. Further studies with larger sample sizes and extended follow-up periods are needed to confirm these results.

Keywords: Secretome; Laser Therapy; Systematic Review; Skin.

RESUMO

Este estudo comparou a eficácia da administração de secretomas utilizando a técnica de microagulhamento versus a administração assistida por laser para o rejuvenescimento da pele facial. A revisão incluiu sete estudos que demonstraram que ambas as abordagens são efetivas na entrega de secretomas. No entanto, o microagulhamento apresentou uma taxa de satisfação do paciente mais alta e menos eventos adversos relatados. Conclui-se que o microagulhamento pode ser uma opção mais amigável e segura para o rejuvenescimento facial. Estudos adicionais com amostras maiores e períodos de acompanhamento mais longos são necessários para confirmar esses resultados.

Palavras-chave: Secretoma; Lasers; Revisão Sistemática; Pele.

Review Article

Authors:

Luh Putu Mahatya Valdini Putri¹
Monica Trifitriana²
Yuli Kurniawati³
Riany Jade Sabrina Toisuta⁴
Erlinda Karyadi⁵

- ¹ Udaya University, Faculty of Medicine, Bali – Bali, Indonesia
- ² Sriwijaya University, Faculty of Medicine, Palembang – South Sumatra, Indonesia
- ³ Sriwijaya University, Department of Dermatology, Venereology and Aesthetics, Palembang – South Sumatra, Indonesia
- ⁴ Jenderal Achmad Yani University, Faculty of Medicine, Bandung – West Java, Indonesia
- ⁵ Kristen Maranatha University, Faculty of Medicine, Bandung – West Java, Indonesia

Correspondence:

Monica Trifitriana
Email: mtrifitriana18@gmail.com / monicatrifitriana@fk.unsri.ac.id

Financial support: None.

Conflict of interest: None.

Submitted on: 01/07/2023

Approved on: 07/01/2024

How to cite this article:

Putri LPMV, Trifitriana M, Kurniawati Y, Toisuta RJS, Karyadi E. T he effectiveness of secretomes delivery using microneedling compared to laser-assisted drug delivery for facial skin rejuvenation: a systematic review. *Surg Cosmet Dermatol.* 2024;16:e20240274.



INTRODUCTION

Skin aging is a natural process caused by a combination of extrinsic and intrinsic factors, leading to wrinkles, loss of elasticity, and other visible changes.^{1,2} One strategy to combat aging is the use of stem cells, such as amniotic membrane stem cells-conditioned medium (AMSC-CM), adipose-derived mesenchymal stem cells (ADMSCs), and human umbilical cord-derived mesenchymal stem cells-conditioned medium (hUC-MSCs-CM).^{3,4} To reduce wrinkles and other photoaging-related facial deformities, AMSC-CM, ADMSC-CM, and hUC-MSCs-CM can stimulate dermal collagen production, growth factor, chemokines, dermal fibroblast proliferation and migration, and epidermal keratinocyte migration.^{5,6,7}

Several treatments, such as microneedling and laser therapy, can promote skin rejuvenation. The fractional CO₂ and erbium lasers are emerging technologies that show potential for improving skin rejuvenation.⁷ The microthermal zone (MTZ) of ablation in the skin facilitates penetration of topical big therapeutic molecules from the surface to the layer of interest while shortening the healing time following laser-induced tissue injury.^{8,9} This study aims to compare the effectiveness of secretome delivery using microneedling versus laser-assisted drug delivery (LADD) for facial skin rejuvenation.

METHOD

A systematic review through various stages: (Figure 1)

Search strategy

We conducted a comprehensive investigation in 2023 to explore the efficacy of delivering secretome through microneedling or laser-assisted drug delivery (LADD) therapy for skin rejuvenation. The search utilized keywords such as “SECRETOME”, “MESENCHYMAL STEM CELL-CONDITIONED MEDIUM”, “AMSC-CM”, “ADMSC-CM”, “hUC-MSCs-CM”, combined with “MICRONEEDLING”, and “LASER ASSISTED DRUG DELIVERY”, including synonyms. Electronic databases, including Pubmed, Cochrane Central Database, ClinicalTrials.gov, and Mendeley, were consulted from their inception up until June 2023. We assessed the retrieved records systematically using predetermined inclusion and exclusion criteria. Initially, four authors (LPM, MT, RJ, and EK) independently scanned all abstracts to identify relevant studies. In case of discrepancies, the remaining two authors (YK and MT) were involved in the final judgment and eligibility assessment by reviewing the full-text articles. Figure 1 provides a flowchart outlining the literature search strategy, following the Preferred Reporting Items for Systematic Reviews guidelines.




FIGURE 1: The flow diagram of meta-analysis

Selection Criteria

This study included all publications in 2023 that investigated the effectiveness of secretome delivery using microneedling or LADD therapy for skin rejuvenation. The selected publications consisted of original studies, excluding review articles, meta-analyses, epidemiological studies, abstracts only, non-English manuscripts, and editorials.

Data Extraction

Two independent authors (MT and LPM) performed the data extraction and quality assessment using a standardized extraction method in an Excel application.

Bias Analysis

We used the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) analysis to assess bias in several journals. Table 1 shows that all journals explicitly defined their population, intervention, comparison, and outcome criteria. Although original studies were the most prevalent, some journals exhibited bias in different aspects. One journal displayed biases in participant data, another had bias related to the intervention, one journal had biases due to missing data, and another had biases associated with reporting. Overall, all the included studies received low scores, indicating a risk of bias.

RESULTS

Study selection

Figure 1 provides an overview of the process used to select the studies. Initially, the search identified a total of 82 articles,

and after removing duplicates, 18 potentially relevant articles remained. Upon reviewing the titles and abstracts, 64 articles were excluded, resulting in seven studies that met the inclusion criteria. There were no disagreements during the study selection process.

Table 1 presents the characteristics of the seven studies that met the inclusion criteria. These studies encompassed various types, including prospective studies, randomized controlled spit-face studies, and analytical experimental controlled clinical trials. Most cases and studies were conducted in Indonesia, with one study from China. Among the 268 patients included in the studies, 240 were women, while the study by Liang *et al.* did not specify the gender of the 28 participants. The studies used microneedling, fractional CO₂ laser, and fractional erbium:YAG laser. The secretomes employed in the studies included AMSC-CM, ADMSCs, and hUC-MSCs-CM.

The effectiveness of included studies

Table 3 shows that microneedling and LADD proved to be effective therapies for delivering secretomes. Microneedling and LADD significantly reduced wrinkles and pore size, improved pigmentation and UV spots, and enhanced moisture and elasticity starting at six weeks.

Adverse events of included studies

Table 2 indicates that both groups experienced adverse events, including erythema, pain, burning sensation, itch, and urticaria. Also, the LADD group reported acne eruption. Microneedling exhibited a higher patient satisfaction rate and lower reported adverse events than the LADD group.

Table 1. ROBINS-I Analysis

Study	Confounding Bias	Participants Bias	Intervention Bias	Missing Data Bias	Outcome Bias	Reporting Bias	Overall Risk Bias
Sari <i>et al.</i> , 2021 ¹⁰	No	No	No	NI	No	No	Low
Yusharyahya <i>et al.</i> , 2023 ¹¹	No	No	Yes	NI	No	Yes	Low
Prakoeswa <i>et al.</i> , 2021 ¹²	No	No	No	NI	No	No	Low
Praharsini <i>et al.</i> , 2020 ¹³	No	Yes	No	NI	No	No	Low
Widianingsih <i>et al.</i> , 2019 ¹⁴	No	No	No	NI	No	No	Low
Liang <i>et al.</i> , 2022 ¹⁵	No	No	No	Yes	No	No	Low
Prakoeswa <i>et al.</i> , 2018 ³	No	No	No	NI	No	No	Low

Note: Bias analysis showed that all journals have clear population, intervention, comparison, and outcome. These journals were mostly the original study for this research. There were 1 journal with participants' data bias, 1 journal with intervention bias, 1 journal with missing data bias, and 1 journal with reporting bias. All of the included studies have a low score according with overall risk bias.

Table 2. Research characteristics involved in the study and side effects of each study

N.	Study (author, year)	Study Design	Country	Gender (M/F)	Type of Stem Cell	Intervention	Study Duration	Number of Session	Session Interval	2 weeks					
										Erythema	Pain	Burn-ing Sensation	Itch	Urti-caria	Acne Erup-tion
1	Sari <i>et al.</i> , 2021 ¹⁰	Prospective study	Indonesia	F (60)	AM-SC-CM	Fractional CO ₂ and MN	12 weeks	3 sessions	FL: 1 month MN: 2 weeks	N/A	N/A	N/A	N/A	N/A	N/A
2	Yusharyaha <i>et al.</i> , 2023 ¹¹	Ran-domized split-face clinical trial	Indonesia	F (30)	ADMSCs	Fractional CO ₂ and MN	6 weeks	3 sessions	2 weeks	MN: 0 (0.0%); FL: 2 (6.7%)	MN: 15 (50.0%); FL: 30 (100.0%)	MN: 4 (13.3%); FL: 22 (73.3%)	MN: 1 (3.3%); FL: 2 (6.7%)	N/A	N/A
3	Prakoewa <i>et al.</i> , 2021 ¹²	One group pre and post-test design model	Indonesia	F (60)	AM-SC-CM	Erbium: YAG and MN	8 weeks	3 sessions	4 weeks	N/A	N/A	N/A	N/A	N/A	N/A
4	Praharsini <i>et al.</i> , 2020 ¹³	Con-trolled split-face	Indonesia	F (33)	AM-SC-CM	Erbium: YAG Fractional	8 weeks	3 sessions	4 weeks	N/A	N/A	N/A	N/A	1	N/A
5	Widianing-sih <i>et al.</i> , 2019 ¹⁴	Ran-domized, controlled split-face study	Indonesia	F (9)	AM-SC-CM	Erbium: YAG Fractional	24 weeks	3 sessions	4 weeks	9 (100%)	7 (77.7%)	N/A	N/A	N/A	2 (22%)
6	Liang <i>et al.</i> , 2022 ¹⁵	Con-trolled and pro-spective study	China	PEO- PLE (28)	hUC- MSCs- CM	MN	10 weeks	5 sessions	2 weeks	1	N/A	N/A	N/A	N/A	N/A
7	Prakoewa <i>et al.</i> , 2018 ³	Analytical experi-mental controlled clinical trial	Indonesia	F (48)	AM-SC-CM	MN	8 weeks	3 sessions	2 weeks	1	N/A	N/A	N/A	1	N/A

*N/A: Not available

TABLE 3: Results of research interventions

N.	Study	Type of Stem Cell	Intervention	Outcome																			
				Wrinkle			Pore Size			Pigmentation			UV Spot			Moisture			Elasticity				
				MIN	FL	vs.	MIN	FL	vs.	MIN	FL	vs.	MIN	FL	vs.	MIN	FL	vs.	MIN	FL	vs.	MIN	FL
1	Sari <i>et al.</i> , 2021 ¹⁰	AM-SC-CM	Fractional CO ₂ and MN	11.90 ± 7.345 vs 0.50 (-11-17)	6.73 ± 2.586 vs 1.00 (-4-19)	vs.	51.20 ± 6.723 vs -2.00 (-9-8)	49.60 ± 4.924 vs 3.50 (-1-10)	vs.	N/A	N/A	14.87 ± 8.569 vs 0.00 (-17-9)	7.77 ± 3.588 vs 0.00 (-10-8)	vs.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
2	Yusharyahya <i>et al.</i> , 2023 ¹¹	ADM-SCs	Fractional CO ₂ and MN	3.50 (9.25) vs -2.50 (7.00)	2.5 (8.00) vs -1.00 (9.00)	vs.	N/A	N/A	vs.	N/A	N/A	N/A	N/A	vs.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
3	Prakoeswa <i>et al.</i> , 2021 ¹²	AM-SC-CM	Erbium:YAG and MN	Janus 1 vs. 2: p value: 0,216; Janus 1 vs. 3: p value: 0,429; Janus 2 vs. 3: p value: 0,846	Janus 1 vs. 2: p value: 0,084; Janus 1 vs. 3: p value: 0,043; Janus 2 vs. 3: p value: 0,000	vs.	Janus 1 vs. 2: p value: 0,023; Janus 1 vs. 3: p value: 0,032; Janus 2 vs. 3: p value: 0,029	Janus 1 vs. 2: p value: 0,023; Janus 1 vs. 3: p value: 0,023; Janus 2 vs. 3: p value: 0,023	vs.	N/A	N/A	Janus 1 vs. 2: p value: 0,38; Janus 1 vs. 3: p value: 0,258; Janus 2 vs. 3: p value: 0,258	Janus 1 vs. 2: p value: 0,04; Janus 1 vs. 3: p value: 0,00; Janus 2 vs. 3: p value: 0,00	vs.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
4	Praharsini <i>et al.</i> , 2020 ¹³	AM-SC-CM	Erbium:YAG Fractional	N/A	4.28 ± 0.38 vs 4.09 ± 0.20	vs.	N/A	6.52 ± 0.57 vs 5.79 ± 0.7	vs.	4.35 ± 1.41 vs 3.09 ± 0.68	N/A	N/A	N/A	vs.	42.2 ± 7.64 vs 59.1 ± 7.94	N/A	N/A	N/A	N/A	N/A	N/A	48.2 ± 14.1 vs 61.7 ± 13.1	
5	Widiamingsih <i>et al.</i> , 2019 ¹⁴	AM-SC-CM	Erbium:YAG Fractional	N/A	19.778 ± 3.89801 vs 18.6667 ± 4.63681	vs.	N/A	48.3333 ± 4.21307 vs 47.1111 ± 3.68932	vs.	N/A	N/A	13.1111 ± 6.99007 vs 11.4444 ± 4.06544	N/A	vs.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6	Liang <i>et al.</i> , 2022 ¹⁵	hUC-MSCs-CM	MN	17.21 (13.24) vs 18.18 (13.38)	N/A	vs.	23.55 (10.52) vs 14.05 (6.11)	N/A	vs.	23.55 (10.52) vs 24.40 (10.77)	N/A	24.39 (7.11) vs 14.47 (5.38)	N/A	vs.	2.18 (5.80) vs 2.07 (6.78)	N/A	N/A	N/A	N/A	N/A	0.56 (0.07) vs 0.57 (0.06)	N/A	N/A
7	Prakoeswa <i>et al.</i> , 2018 ³	AM-SC-CM	MN	13.92 ± 6.639 vs 12.13 ± 7.011	N/A	vs.	53.17 ± 4.565 vs 49.63 ± 11.193	N/A	vs.	N/A	N/A	17.17 ± 8.646 vs 14.54 ± 8.748	N/A	vs.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

*N/A: Not available

TABLE 4: The comparison of microneedling with laser therapy

Comparison	Microneedling	LADD
Type of treatment	Non-laser-based treatment	Laser-based treatment
Technique	Uses a device with tiny needles to create microinjury for providing skin access to topical drugs	Uses a laser to create microthermal zone for providing skin access to topical drugs
Targeted	Wrinkle, fine lines, acne scars, overall skin rejuvenation	Wrinkle, fine lines, age spots, acne scars
Recovery time	Minimal downtime, some redness and mild swelling	Several days to a week for redness and peeling
Pain/discomfort	May cause mild to moderate discomfort during the treatment	May cause discomfort during and after the treatment
Effectiveness	Effective, but may require several treatments for best results	Highly effective, noticeable, results in a few weeks
Cost	Less expensive to laser therapy	Expensive

The comparison of microneedling and laser therapy

Table 4 reveals that LADD was slightly more effective than microneedling in facial skin rejuvenation, although the difference was not statistically significant. Microneedling demonstrated fewer adverse events and lower costs compared to LADD.

DISCUSSION

Microneedling and LADD procedures have been used in cosmetic dermatology for several goals, including skin aging therapy. Both methods successfully construct vertical microtunnels into the dermis, allowing transdermal topical drug delivery.⁶⁻⁸

LADD is widely known for its capacity to increase collagen formation and remodeling, allowing photoaged skin's aberrant collagen fibers to rearrange as needed while microneedle creates microinjury and generates a regulated skin injury with little epidermal damage, which stimulates the dermal wound healing cascade (inflammation, proliferation, and remodeling).^{1,2,6}

Mild erythema, localized edema, and skin peeling are the most frequent and anticipated adverse events of microneedling and typically resolve within 48 to 72 hours.⁶ Compared to microneedling, LADD had more unfavorable effects, such as longer

erythema, discomfort, burning sensation, and itch. In light of these findings, dermatologists can select between Microneedling and LADD to distribute secretome, given that LADD may not be available in every clinic due to high costs, while microneedling may be available in all settings. Microneedling is a beneficial option over more invasive procedures such as laser skin resurfacing and deep chemical peeling due to its quick post-treatment recovery, low adverse events profile, and remarkable clinical results.^{2,5-7} To improve the therapeutic effect further, the AMSC-CM, ADMSCs, and hUC-MSCs-CM are delivered through laser channels. These cells exert their anti-wrinkle effects by upregulating procollagen type I production and inhibiting matrix metalloproteinase 1 (MMP-1) secretion, which is responsible for the degradation of collagen fibers. The current study breaks down the skin barrier.^{4,5}

CONCLUSION

Microneedling and laser-assisted drug delivery are effective methods for delivering secretomes for skin rejuvenation. However, microneedling may be a more patient-friendly and safer option. Further studies with larger sample sizes and longer follow-up periods are needed to confirm these findings. ●

REFERENCES:

1. Estebasari F, Dastoorpoor M, Khalifehkandi ZR, Nouri A, Mostafaei D, Hosseini M, *et al.* The concept of successful aging: a review article. *Curr Aging Sci.* 2020;13(1):4–10.
2. El-Domyati M, Moftah NH, Nasif GA, Ragaie MH, Ibrahim MR, Ameen SW. Amniotic fluid derived mesenchymal stem cell products combined with microneedling for acne scars: a split face clinical, histological, and histometric study. *J Cosmet Dermatol.* 2019;18(5):1300-1306.
3. Prakoeswa CRS, Pratiwi FD, Herwanto N, Citrashanty I, Indramaya DM, Murtiastutik D, *et al.* The effects of amniotic membrane stem cell conditioned medium on photoaging. *J Dermatol Treat.* 2019;30(5):478-482.
4. Damayanti RH, Rusdiana T, Wathoni N. Mesenchymal stem cell secretome for dermatology application: a review. *Clin Cosmet Investig Dermatol.* 2021;14:1401–1412.
5. Xia J, Minamino S, Kuwabara K, Arai S. Stem cell secretome as a new booster for regenerative medicine. *Biosci Trends.* 2019;13(4):299–307.
6. Kim YJ, Seo DH, Lee SH, Lee SH, An GH, Ahn HJ, *et al.* Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin. *Biochem Biophys Rep.* 2018;16:96–102.
7. El-Domyati M, Abdel-Wahab H, Hossam A. Combining microneedling with other minimally invasive procedures for facial rejuvenation: a split-face comparative study. *Int J Dermatol.* 2018;57(11):1324-1334.
8. Sitohang IB, Sirait SA, Safira FD. Fractional carbon dioxide laser for treating hypertrophic scars: a systematic review of randomized trials. *Australas J Dermatol.* 2022;63(1):27–35.
9. Lee J, Kim J. Emerging technologies in scar management: laser-assisted delivery of therapeutic agents. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG, editors. *Textbook on scar management.* Cham: Springer; 2020. p.444-445.
10. Sari M, Umborowati MA, Citrashanty I, Indramaya DM, Rantam FA, Listiawan MY, *et al.* The efficacy of fractional CO2 laser and microneedling - amniotic membrane stem cell conditioned media for photoaging. *Mal J Med Health Sci.* 2021;17(SUPP6):91-97.
11. Yusharyahya SN, Japranata VV, Sitohang IBS, Legiawati L, Novianto E, Suseno LS, *et al.* A comparative study on adipose-derived mesenchymal stem cells secretome delivery using microneedling and fractional CO2 laser for facial skin rejuvenation. *Clin Cosmet Investig Dermatol.* 2023;16:387–395.
12. Prakoeswa CRS, Oktaviyanti RN, Nugroho WT, Pratiwi FD, Rusyati LM, Praharsini IGAA, *et al.* The efficacy of fractional erbium:YAG laser (2940 nm) compared to microneedling of topical amniotic membrane stem cell conditioned medium (AMSC- CM) for photoaging. *Ind J For Med Toxic.* 2021;15(2):2161-2167.
13. Praharsini IGAA, Indira IGAAE, Prakoeswa CRS, Adiguna MS, Rusyati LM, Umborowati MA, *et al.* Effication of amniotic membrane topical stem cell-conditioned medium combined with YAG erbium fractional laser 2940 nm in photoaging skin. *Indo J Biomed Sci.* 2020;14(2):44–7.
14. Widianingsih NPS, Setyaningrum T, Prakoeswa CRS. The efficacy and safety of fractional erbium YAG laser combined with topical amniotic membrane stem cell (AMSC) metabolite product for facial rejuvenation: a controlled, split-face study. *Dermatol Reports.* 2019;11(s1):8036.
15. Liang X, Li J, Yan Y, Xu Y, Wang X, Wu H, *et al.* Efficacy of microneedling combined with local application of human umbilical cord-derived mesenchymal stem cells conditioned media in skin brightness and rejuvenation: a randomized controlled split-face study. *Frontiers Med.* 2022;9.

AUTHOR'S CONTRIBUTION:

Luh Putu Mahatya Valdini Putri  ORCID 0009-0008-8870-7700

Study design and planning; Preparation and writing of the manuscript; Collecting, analyzing, and interpreting data; Effective participation in research orientation; Intellectual participation in propaedeutic and/or therapeutic conduct of studied cases; Critical literature review.

Monica Trifitriana  ORCID 0000-0002-9454-1961

Statistical analysis; Approval of the final version of the manuscript; Study design and planning; Preparation and writing of the manuscript; Collecting, analyzing, and interpreting data; Intellectual participation in propaedeutic and/or therapeutic conduct of studied cases; Critical literature review; Critical review of the manuscript.

Yuli Kurniawati  ORCID 0000-0001-7587-5504

Study design and planning; Critical literature review; Critical review of the manuscript.

Riany Jade Sabrina Toisuta  ORCID 0009-0008-9316-9281

Preparation and writing of the manuscript; Collecting, analyzing, and interpreting data; Effective participation in research orientation; Intellectual participation in propaedeutic and/or therapeutic conduct of studied cases.

Erlinda Karyadi  ORCID 0009-0008-5761-7534

Preparation and writing of the manuscript; Collecting, analyzing, and interpreting data; Effective participation in research orientation; Intellectual participation in propaedeutic and/or therapeutic conduct of studied cases.